查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1968489

CGRP抑制剂市场－全球产业规模、份额、趋势、机会、预测：治疗方法、给药途径、最终用户、地区和竞争格局，2021-2031年

CGRP Inhibitor Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment, By Route of Administration, By End-User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球 CGRP 抑制剂市场预计将从 2025 年的 36.2 亿美元成长到 2031 年的 63.2 亿美元，复合年增长率达到 9.73%。

这些抑制剂属于一类特殊的药物疗法，包括单株抗体和小分子拮抗剂，它们透过抑制抑钙素基因相关胜肽（CGRP）或其受体来预防偏头痛的发作。推动这一增长的关键因素包括全球慢性头痛疾病发生率的上升，以及临床治疗策略从急性症状管理到预防性治疗策略的显着转变。此外，与传统曲坦类药物相比，安全性更高的治疗方法越来越受到患者的青睐，这也促进了这些标靶治疗的应用。

市场概览
预测期 2027-2031
市场规模：2025年 36.2亿美元
市场规模：2031年 63.2亿美元
复合年增长率：2026-2031年 9.73%
成长最快的细分市场 口服
最大的市场 北美洲

另一方面，对偏头痛症状的偏见和低估是市场成长的主要障碍，常常导致诊断延误和患者难以获得最先进治疗。这种认知不足限制了符合处方治疗条件的患者族群。欧洲偏头痛和头痛协会2024年的报告指出，74%的偏头痛患者认为他们的病情没有得到医疗专业人员的重视。因此，这些专业人员认知方面的障碍严重阻碍了昂贵的CGRP抑制剂疗法的广泛应用和医疗覆盖范围。

市场驱动因素

全球偏头痛和头痛疾病盛行率的不断上升是推动市场扩张的主要动力，也因此迫切需要疗效优于特异性治疗方法的标靶治疗。这种疾病带来的沉重负担，包括剧烈疼痛和经济影响，正促使人们转向特定机制的干预措施，例如CGRP抑制剂，以满足尚未充分满足的医疗需求。环境因素加剧了这一趋势。正如《国家地理》杂誌2025年12月发表的题为《偏头痛兴起之谜》的文章中所述，美国头痛协会年会的一项调查显示，环境温度每升高10华氏度，头痛的发生率就会增加6%。这种频率的增加扩大了潜在患者群体，凸显了製定强有力的预防策略的必要性。世界卫生组织（WHO）2025年10月发布的一份情况说明书进一步证实了这一规模，该说明书指出「头痛疾病影响着全球约40%的人口」。

此外，药物递送系统的创新，特别是口服小分子拮抗剂（如吉泮）的研发，为注射单株抗体提供了非侵入性的替代方案，从而加速了市场成长。口服给药的便利性提高了患者的依从性，并扩大了以往只能使用疗效较差的急性期治疗方案的阵发性偏头痛病例的处方机会。这项技术进步显着提升了行业收入；例如，艾伯维在其2025年1月发布的2024年全年及第四季度财务业绩报告中宣布，其口服CGRP抑製剂产品组合（优布瑞和克瑞普塔）的全球总合销售额已达到16.64亿美元。如此快速的商业性化应用表明，市场明显偏好更便捷的给药方式，也证明了製药业向传统注射剂以外的给药途径进行策略性扩张的合理性。

市场挑战

对偏头痛的偏见和轻视是全球CGRP抑制剂市场成长的重大障碍。这种持续存在的负面认知阻碍了患者寻求专业医疗建议，导致他们依赖疗效较差的急性治疗而非预防措施。当偏头痛被简单地视为头痛时，患者就更不愿意咨询神经科医生正是高级CGRP抑制剂的主要处方医生。这种孤立实际上造成了患者就医管道的瓶颈，使得相当一部分合格的患者无法获得准确的诊断和先进的药物。

此外，社会上的怀疑态度对医疗服务的可近性和报销机制产生了负面影响，从而限制了昂贵治疗方法的商业性化应用。根据美国偏头痛基金会2024年的数据，31.7%的偏头痛患者经常遭受社会歧视，而这种歧视与更高的残疾负担有关。这种普遍存在的认知不足降低了支付方核准昂贵生物製药保险的迫切性。因此，市场难以将疾病的高发生率转化为实际的收入成长，而社会上的忽视也限制了这些标靶治疗的推广。

市场趋势

将急性治疗和预防性治疗相结合，从根本上改变了传统的治疗模式，改变了市场结构。这一趋势的特征是双效疗法的普及，这种疗法只需一种药物即可控制急性发作并预防復发，从而减轻患者的用药负担并提高依从性。对于头痛发作频率波动的患者而言，这种柔软性是替代传统复杂多联合治疗的重要选择。灵活口服製剂的优异表现证明了这一转变的商业性成功。正如辉瑞在2024年10月发布的2024年第三季财报中所述，双适应症CGRP抑制剂Nurtec ODT/Vydura的全球销售收入年增45%，这证实了临床上对能够提供机制特异性控制的简化治疗方法的偏好。

同时，联合治疗作为一种治疗单药治疗无效的难治性病例的方法，正日益受到重视。口服小分子药物注重便利性，但有一部分患者族群需要高效的静脉製剂，这些製剂通常与其他治疗方法（例如A型肉毒桿菌）合併使用，以控制症状。这种增强策略正在输注药物领域创造显着价值，这与大批量口服药物市场截然不同。对强效、由医疗专业人员给药的治疗方法的需求得到了强劲销售的支撑。根据灵北製药于2024年11月发布的“2024年第一季至第三季中期报告”，其静脉注射CGRP抑制剂Vyepti的销售额同比增长76%，表明市场对针对严重和难治性患者群体的先进给药形式的依赖性日益增强。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球CGRP抑制剂市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 治疗方法（预防性、急性治疗）
    • 给药途径（口服、鼻内、静脉注射）
    • 依最终用户（医院、药局、专科诊所）划分
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美CGRP抑制剂市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲CGRP抑制剂市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区CGRP抑制剂市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲CGRP抑制剂市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲CGRP抑制剂市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章 全球CGRP抑制剂市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Eli Lilly and Company
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd
  • AbbVie Inc.
  • Amgen Inc
  • Novartis AG
  • Allergan
  • Biohaven Pharmaceutical Holding Company Ltd.
  • Sun Pharmaceutical Industries Ltd

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 19245

The Global CGRP Inhibitor Market is projected to expand from USD 3.62 Billion in 2025 to USD 6.32 Billion by 2031, achieving a CAGR of 9.73%. These inhibitors represent a specialized category of pharmacotherapies, including monoclonal antibodies and small molecule antagonists, which function by blocking calcitonin gene-related peptides or their receptors to avert migraine onset. Key factors propelling this growth include the rising global incidence of chronic headache disorders and a distinct clinical transition from acute symptom management toward preventive care strategies. Furthermore, the preference for therapies offering better safety profiles than traditional triptans is bolstering the adoption of these targeted treatments.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 3.62 Billion
Market Size 2031USD 6.32 Billion
CAGR 2026-20319.73%
Fastest Growing SegmentOral
Largest MarketNorth America

Conversely, market growth faces substantial hurdles due to the stigmatization and trivialization of migraine conditions, which often result in postponed diagnoses and limited access to cutting-edge treatments. This lack of validation restricts the eligible patient base for prescription therapies, as highlighted by the European Migraine & Headache Alliance in 2024, which noted that 74% of migraine patients felt their condition was not taken seriously by medical professionals. Consequently, these barriers to professional acknowledgement significantly hinder the widespread adoption and reimbursement of premium CGRP inhibitor therapies.

Market Driver

The rising global prevalence of migraine and headache disorders serves as the primary engine for market expansion, generating urgent demand for targeted therapeutics with efficacy superior to non-specific treatments. The substantial burden of this disease, marked by debilitating pain and economic consequences, has prompted a shift toward mechanism-specific interventions like CGRP inhibitors that satisfy high unmet medical needs. Environmental factors are aggravating this trend; as reported by National Geographic in December 2025 regarding the 'mysterious rise of migraines,' research from the American Headache Society's annual meeting indicated a 6% rise in headache occurrence for every 10-degree Fahrenheit increase in outdoor temperature. This increasing frequency enlarges the potential patient population, necessitating strong preventive strategies, a scale underscored by the World Health Organization's October 2025 fact sheet stating that headache disorders impact roughly 40% of the global population.

Furthermore, innovations in drug delivery systems, especially the creation of oral small molecule antagonists known as gepants, have hastened market growth by providing non-invasive alternatives to injectable monoclonal antibodies. The ease of oral administration improves patient adherence and expands prescribing opportunities to cover episodic migraine cases that were historically treated with less effective acute medications. This technological evolution is fueling significant sector revenue; for instance, AbbVie reported in its 'Full-Year and Fourth-Quarter 2024 Financial Results' in January 2025 that combined global net revenues for its oral CGRP portfolio, comprising Ubrelvy and Qulipta, hit $1.664 billion. Such rapid commercial adoption illustrates the market's clear preference for convenient administration methods, validating the pharmaceutical industry's strategic expansion into delivery mechanisms beyond traditional injectables.

Market Challenge

The stigmatization and trivialization of migraine disorders present a significant obstacle to the growth of the Global CGRP Inhibitor Market. This pervasive invalidation frequently deters patients from pursuing specialized medical advice, leading them to depend on ineffective acute treatments instead of seeking preventive measures. When the condition is minimized as merely a headache, patients are unlikely to consult neurologists, who serve as the primary prescribers of advanced CGRP inhibitors. This separation effectively creates a bottleneck in the patient pipeline, precluding a substantial segment of the eligible population from obtaining accurate diagnoses and accessing advanced pharmacotherapies.

Additionally, societal skepticism adversely impacts healthcare utilization and reimbursement structures, thereby restricting the commercial uptake of premium treatments. Data from the American Migraine Foundation in 2024 revealed that 31.7% of individuals with active migraine frequently experienced stigma, a factor correlated with higher disability burdens. This widespread lack of acknowledgement reduces the urgency for payers to authorize coverage for these expensive biologics. As a result, the market encounters difficulties in translating high disease prevalence into tangible revenue growth, as the social dismissal of the condition limits the adoption of these targeted interventions.

Market Trends

The convergence of acute and preventive prescribing is fundamentally reshaping the market, transitioning away from the historical model of separated treatment regimens. This trend is characterized by the widespread adoption of dual-action therapies that enable patients to manage active migraine attacks and prevent future occurrences with a single pharmacological agent, thereby lowering pill burden and enhancing compliance. This flexibility fills a crucial gap for patients with variable headache frequencies who previously managed complex polypharmacy regimens. The commercial success of this shift is demonstrated by the performance of flexible oral agents; as noted in Pfizer's 'Third-Quarter 2024 Financial Results' from October 2024, global operational revenue for its dual-indicated CGRP inhibitor, Nurtec ODT/Vydura, rose by 45% year-over-year, confirming the clinical preference for streamlined interventions that provide mechanism-specific control.

Concurrently, the increasing use of combination therapies is gaining momentum as a method to treat refractory cases that do not respond to monotherapy. While oral small molecules focus on convenience, there is a distinct and expanding patient sub-segment requiring high-efficacy intravenous formulations, frequently administered in conjunction with other modalities like onabotulinumtoxinA to achieve symptom suppression. This intensification strategy generates significant value within the infusion category, distinguishing it from the mass-market oral sector. The demand for potent, provider-administered options is supported by strong sales figures; according to Lundbeck's 'Interim Report for the First Nine Months of 2024' released in November 2024, revenue for its intravenous CGRP inhibitor, Vyepti, increased by 76% over the prior year, highlighting the market's growing reliance on advanced delivery formats for the most severe and resistant patient profiles.

Key Market Players

  • Eli Lilly and Company
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd
  • AbbVie Inc.
  • Amgen Inc
  • Novartis AG
  • Allergan
  • Biohaven Pharmaceutical Holding Company Ltd.
  • Sun Pharmaceutical Industries Ltd

Report Scope

In this report, the Global CGRP Inhibitor Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

CGRP Inhibitor Market, By Treatment

  • Preventive
  • Acute

CGRP Inhibitor Market, By Route of Administration

  • Oral
  • Nasal
  • Intravenous

CGRP Inhibitor Market, By End-User

  • Hospitals
  • Pharmacies
  • Specialty Clinics

CGRP Inhibitor Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global CGRP Inhibitor Market.

Available Customizations:

Global CGRP Inhibitor Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global CGRP Inhibitor Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment (Preventive, Acute)
    • 5.2.2. By Route of Administration (Oral, Nasal, Intravenous)
    • 5.2.3. By End-User (Hospitals, Pharmacies, Specialty Clinics)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America CGRP Inhibitor Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment
    • 6.2.2. By Route of Administration
    • 6.2.3. By End-User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States CGRP Inhibitor Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment
        • 6.3.1.2.2. By Route of Administration
        • 6.3.1.2.3. By End-User
    • 6.3.2. Canada CGRP Inhibitor Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment
        • 6.3.2.2.2. By Route of Administration
        • 6.3.2.2.3. By End-User
    • 6.3.3. Mexico CGRP Inhibitor Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment
        • 6.3.3.2.2. By Route of Administration
        • 6.3.3.2.3. By End-User

7. Europe CGRP Inhibitor Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment
    • 7.2.2. By Route of Administration
    • 7.2.3. By End-User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany CGRP Inhibitor Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment
        • 7.3.1.2.2. By Route of Administration
        • 7.3.1.2.3. By End-User
    • 7.3.2. France CGRP Inhibitor Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment
        • 7.3.2.2.2. By Route of Administration
        • 7.3.2.2.3. By End-User
    • 7.3.3. United Kingdom CGRP Inhibitor Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment
        • 7.3.3.2.2. By Route of Administration
        • 7.3.3.2.3. By End-User
    • 7.3.4. Italy CGRP Inhibitor Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Treatment
        • 7.3.4.2.2. By Route of Administration
        • 7.3.4.2.3. By End-User
    • 7.3.5. Spain CGRP Inhibitor Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Treatment
        • 7.3.5.2.2. By Route of Administration
        • 7.3.5.2.3. By End-User

8. Asia Pacific CGRP Inhibitor Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment
    • 8.2.2. By Route of Administration
    • 8.2.3. By End-User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China CGRP Inhibitor Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment
        • 8.3.1.2.2. By Route of Administration
        • 8.3.1.2.3. By End-User
    • 8.3.2. India CGRP Inhibitor Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment
        • 8.3.2.2.2. By Route of Administration
        • 8.3.2.2.3. By End-User
    • 8.3.3. Japan CGRP Inhibitor Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment
        • 8.3.3.2.2. By Route of Administration
        • 8.3.3.2.3. By End-User
    • 8.3.4. South Korea CGRP Inhibitor Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Treatment
        • 8.3.4.2.2. By Route of Administration
        • 8.3.4.2.3. By End-User
    • 8.3.5. Australia CGRP Inhibitor Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Treatment
        • 8.3.5.2.2. By Route of Administration
        • 8.3.5.2.3. By End-User

9. Middle East & Africa CGRP Inhibitor Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment
    • 9.2.2. By Route of Administration
    • 9.2.3. By End-User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia CGRP Inhibitor Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment
        • 9.3.1.2.2. By Route of Administration
        • 9.3.1.2.3. By End-User
    • 9.3.2. UAE CGRP Inhibitor Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment
        • 9.3.2.2.2. By Route of Administration
        • 9.3.2.2.3. By End-User
    • 9.3.3. South Africa CGRP Inhibitor Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment
        • 9.3.3.2.2. By Route of Administration
        • 9.3.3.2.3. By End-User

10. South America CGRP Inhibitor Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment
    • 10.2.2. By Route of Administration
    • 10.2.3. By End-User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil CGRP Inhibitor Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment
        • 10.3.1.2.2. By Route of Administration
        • 10.3.1.2.3. By End-User
    • 10.3.2. Colombia CGRP Inhibitor Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment
        • 10.3.2.2.2. By Route of Administration
        • 10.3.2.2.3. By End-User
    • 10.3.3. Argentina CGRP Inhibitor Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment
        • 10.3.3.2.2. By Route of Administration
        • 10.3.3.2.3. By End-User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global CGRP Inhibitor Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Eli Lilly and Company
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Pfizer Inc.
  • 15.3. Teva Pharmaceutical Industries Ltd
  • 15.4. AbbVie Inc.
  • 15.5. Amgen Inc
  • 15.6. Novartis AG
  • 15.7. Allergan
  • 15.8. Biohaven Pharmaceutical Holding Company Ltd.
  • 15.9. Sun Pharmaceutical Industries Ltd

16. Strategic Recommendations

17. About Us & Disclaimer